



ASX Announcement

27 June 2025

Section 708A Cleansing Statement

This Notice is given by Atomo Diagnostics Limited (ASX: AT1) (Atomo or the Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act):

The Company hereby confirms that:

- a) it has today issued a total of 36,259,457 fully paid ordinary shares (Shares) to new and existing professional, sophisticated and other exempt investors including a Director at an issue price of \$0.0185 (1.85 cents) per Share as previously announced on 24 April 2025.
- b) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- d) as at the date of this notice, the Company has complied with:
 - i. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - ii. section 674 and 674A of the Act; and
- e) as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Act) which is required to be disclosed by the Company.

The details of this allotment can be found within the Appendix 2A also announced on this day.

The Company has issued a further issued 14,723,685 Shares pursuant to the Share Purchase Plan announced on 24 April 2024.

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place



for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com